Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | ALK R1275Q |
| Therapy | Conteltinib |
| Indication/Tumor Type | Advanced Solid Tumor |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ALK R1275Q | Advanced Solid Tumor | predicted - sensitive | Conteltinib | Preclinical - Biochemical | Actionable | In a preclinical study, Conteltinib (CT-707) inhibited ALK R1275Q activity in an in vitro assay (PMID: 36424628). | 36424628 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (36424628) | Conteltinib (CT-707) in patients with advanced ALK-positive non-small cell lung cancer: a multicenter, open-label, first-in-human phase 1 study. | Full reference... |